There were 1,742 press releases posted in the last 24 hours and 426,872 in the last 365 days.

Aspira Women’s Health to Participate at the Upcoming MicroCap Rodeo Windy City Roundup 2022

AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will present and be available for 1x1 meetings at the MicroCap Rodeo Presents Windy City Roundup 2022 conference taking place in-person on October 12-13, 2022 in Chicago, IL. Details for the event are below:

Microcap Rodeo Presents Windy City Roundup 2022
Date: Wednesday, October 12, 2022
Time: 9:30 am Central Time / 10:30 am Eastern Time
Webcast: click HERE

To receive additional information, request an invitation or to schedule a 1x1 meeting, please email angie.goertz@issuerdirect.com. Investors may also register for the event HERE.

A link to the live event also will be available on the Events & Presentation page of the Aspira Women’s Health Investor Relations website.

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc.SM is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus® combines our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX™ testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is working to deliver a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development include OVAWatch™ and EndoCheck™. To improve patient accessibility, Aspira Women’s Health has launched our Aspira SynergySM technology transfer platform to empower health systems, academics, regional labs, and physician group labs to conduct genetic and specialty tests in-house. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact: 
Ashley R. Robinson  
LifeSci Advisors, LLC  
Tel: 617-430-7577 
Arr@lifesciadvisors.com


Primary Logo